Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Клинические последствия замедленного опорожнения желудка при применении агонистов рецептора ГПП-1 и тирзепатида
2024-10-10
SCID: 54.1/xnrfx3gb
Discuss with AI
GLP-1 receptor agonistsdelayed gastric emptyingpulmonary aspirationretained gastric contentstirzepatide
Figures from the paper
Abstract (AI)
CONTEXT: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are established therapeutics for type 2 diabetes and obesity. Among other mechanisms, they slow gastric emptying and motility of the small intestine. This helps to limit postprandial glycemic excursions and reduce chylomicron formation and triglyceride absorption. Conversely, motility effects may have detrimental consequences, eg, retained gastric contents at endoscopy or general anesthesia, potentially complicated by pulmonary aspiration or bowel obstruction. DATA ACQUISITION: We searched the PubMed database for studies involving GLP-1RA therapy and adverse gastrointestinal/biliary events. DATA SYNTHESIS: Retained gastric contents at the time of upper gastrointestinal endoscopy are found more frequently with GLP-1 RAs but rarely are associated with pulmonary aspiration. Well-justified recommendations for the periprocedural management of GLP-1RAs (eg, whether to withhold these medications and for how long) are compromised by limited evidence. Important aspects to be considered are (1) their long half-lives, (2) the capacity of GLP-1 receptor agonism to slow gastric emptying even at physiological GLP-1 concentrations, (c) tachyphylaxis observed with prolonged treatment, and (d) the limited effect on gastric emptying in individuals with slow gastric emptying before initiating treatment. Little information is available on the influence of diabetes mellitus itself (ie, in the absence of GLP-1 RA treatment) on retained gastric contents and pulmonary aspiration. CONCLUSION: Prolonged fasting periods regarding solid meal components, point-of-care ultrasound examination for retained gastric content, and the use of prokinetic medications like erythromycin may prove helpful and represent an important area needing further study to increase patient safety for those treated with GLP-1 RAs.
Key Findings
1
Evidence is insufficient to establish well-supported periprocedural recommendations regarding whether and how long GLP-1 receptor agonists should be withheld.
2
GLP-1 receptor agonists and tirzepatide delay gastric and small-intestinal motility, reducing postprandial glycemic excursions, chylomicron formation, and triglyceride absorption.
3
Prolonged solid-food fasting, point-of-care gastric ultrasound, and prokinetic agents such as erythromycin may improve procedural safety, but require further study.
4
Retained gastric contents during upper gastrointestinal endoscopy occur more frequently in GLP-1 receptor agonist users, but pulmonary aspiration is rarely reported.
5
The clinical impact of delayed gastric emptying depends on long drug half-lives, physiological sensitivity to GLP-1 agonism, treatment-related tachyphylaxis, and baseline gastric emptying rates.
Research Object
GLP-1 receptor agonist therapy (including tirzepatide) and its effects on gastric emptying/motility in patients treated for type 2 diabetes and obesity
Research Subject
Clinical consequences of treatment-induced delayed gastric emptying and altered gastrointestinal motility, including retained gastric contents, pulmonary aspiration, and bowel obstruction risks
Publication Details
Publication Date
2024-10-10
Journal
Publisher
ISSN
Cited by
215
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai3
Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia2024
ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists2023
Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control2022
Cited by3
The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications2026
Preoperative management algorithm for endoscopic or surgical interventions in patients receiving incretin mimetics2026
Perioperative risks of glucagon-like peptide-1 receptor agonists and their implications in airway management using supraglottic airway devices2026